C. Reitmann

No Meaningful Drug Interactions with Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Coadministration

W. Kraft, K. Yee, M. Iwamoto, 2019, Antiviral therapy.

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor

P. Angus, E. Gane, T. Marbury, 2017, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic Interaction of HCV Protease Inhibitor MK-5172 and Ritonavir in Healthy subjects

J. Wagner, J. Denef, J. Hoon, 2013 .

Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
.

K. Lasseter, T. Marbury, R. Wrishko, 2017, International journal of clinical pharmacology and therapeutics.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy

L. Webster, P. Jumes, J. Butterton, 2018, Clinical and translational science.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy

L. Webster, P. Jumes, J. Butterton, 2018, Clinical and translational science.

Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.

R. Nachbar, A. Hüser, E. Gane, 2018, Clinical therapeutics.